Finally, we demonstrate that the anti-tumor effects of pyrvinium in BP-CML are independent of CK1α inhibition and are largely attributed to its inhibition of mitochondrial respiration. This evidence concerns the gene CSNK1A1 and chronic myelogenous leukemia, BCR-ABL1 positive.